Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments
enVVeno Medical (NASDAQ: NVNO) announced results from an independent, peer-reviewed health economic analysis in the Journal of Vascular Surgery: Venous and Lymphatic Disorders evaluating prosthetic venous valve replacement for severe deep venous reflux.
Rhea-AI Summary
enVVeno Medical (NASDAQ: NVNO) announced results from an independent, peer-reviewed health economic analysis in the Journal of Vascular Surgery: Venous and Lymphatic Disorders evaluating prosthetic venous valve replacement for severe deep venous reflux. The modeled five-year analysis found enVVeno’s first-generation VenoValve economically dominant versus compression therapy and wound care, projecting over $32,000 average healthcare savings and about 2.2 fewer venous ulcers per patient, plus improved QALYs and lower overall costs. The study estimated roughly $4,100 savings per rVCSS point of improvement and suggested potential annual system-wide savings of about $5.9 billion with broader venous valve replacement use, supporting the health-economic rationale for the company’s investigational, minimally invasive enVVe system now in the TAVVE pivotal trial.
Positive
- $32,000+ projected five-year healthcare savings per patient with VenoValve versus standard care
- Modeled avoidance of approximately 2.2 venous ulcers per patient over five years
- Projected healthcare savings of about $4,100 per rVCSS point of clinical improvement
- Publication estimates potential $5.9 billion annual savings with broader venous valve replacement adoption
- TAVVE pivotal trial underway to evaluate minimally invasive enVVe replacement venous valve
Negative
- None.
Details
Market reaction after health economic study: NVNO +4.21% in the Aug 4 session
In the Aug 4 session, NVNO gained 4.21%, reflecting a moderate positive market reaction. Argus tracked a peak move of +6.8% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Projected savings per patient
- more than $32,000
- over five years versus standard of care
- Venous ulcers avoided
- approximately 2.2 fewer venous ulcers per patient
- versus standard of care
- Savings per rVCSS point
- approximately $4,100
- per rVCSS point of clinical improvement
- Cost-effectiveness timing
- approximately Year 2
- treatment became cost-effective
- Net savings timing
- between Years 2 and 3
- projected net healthcare savings
- Annual healthcare savings
- approximately $5.9 billion
- estimated with broader adoption of effective venous valve replacement therapy
Historical Context
-
Virtual Investor segment highlighted newly issued enVVe patent and pivotal-trial progress.
-
U.S. patent covered core enVVe valve, support-frame, crimping, and delivery components.
-
Company scheduled a Webull webinar covering FDA IDE approval and pivotal-trial plans.
-
CEO scheduled a Virtual Investor Closing Bell discussion of FDA IDE approval.
-
FDA granted IDE approval for a U.S. pivotal replacement-venous-valve study.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
quality-adjusted life years medical
investigational device exemption regulatory
transcatheter technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Published economic health study shows both short- and long-term cost-effectiveness of replacement venous value therapy versus standard-of-care treatments for deep venous CVI, generating compelling evidence that will be used to support future coverage determinations and reimbursement policies for enVVeno Medical's enVVe non-surgical replacement venous valve
Publication Highlights:
Peer-reviewed publication in the Journal of Vascular Surgery: Venous and Lymphatic Disorders
More than
$32,000 projected healthcare savings per patient over five yearsApproximately 2.2 fewer venous ulcers per patient compared to standard of care
Approximately
$4,100 projected cost savings per each rVCSS* point of clinical improvementEconomically dominant versus compression therapy and wound care in the modeled analysis
Approximately
$5.9 billion estimated annual healthcare savings with broader adoption of effective venous valve replacement therapy
*rVCSS (revised Venous Clinical Severity Score) is a validated clinical tool used to evaluate disease severity and treatment response in patients with chronic venous disease.
IRVINE, CA / ACCESS Newswire / August 4, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today highlighted the publication of a landmark, peer-reviewed health economic analysis in the Journal of Vascular Surgery: Venous and Lymphatic Disorders demonstrating the potential clinical and economic benefits of venous valve replacement therapy for patients with severe deep venous reflux.
The publication titled, "Cost-effectiveness of a prosthetic venous valve versus compression therapies and wound care for treatment of infra-inguinal deep vein reflux," concluded that venous valve replacement therapy has the potential to improve patient outcomes while reducing overall healthcare costs compared with current conservative management. The analysis found that VenoValve, enVVeno's first-generation surgical venous valve technology, was economically dominant versus standard of care over a five-year period, projecting average healthcare savings of more than
The peer-reviewed publication further highlighted the significant burden of chronic deep venous insufficiency and estimated that broader adoption of effective venous valve replacement therapy could translate into approximately
"Publication in a peer-reviewed scientific journal represents one of the strongest forms of independent scientific validation, as the research undergoes rigorous evaluation by experts in the field," said Robert Berman, Chief Executive Officer of enVVeno Medical. "This first-of-its-kind, landmark economic study focused solely on the costs of treating deep venous CVI and will provide compelling evidence for a technology like our enVVe system, compared to standard of care treatments. Once we have the data that we need from the TAVVE pivotal trial, we can apply that clinical data to the results of this published health economic study to make a compelling argument for broad reimbursement coverage."
Chronic deep venous insufficiency affects millions of patients worldwide and remains one of the largest unmet needs in vascular medicine. As venous valves fail, patients often experience chronic pain, swelling, skin changes, recurrent venous leg ulcers and declining quality of life. Current treatment options primarily rely on lifelong compression therapy and wound care designed to manage symptoms rather than correct the underlying cause of disease.
Earlier this year, enVVeno received FDA Investigational Device Exemption (IDE) approval to initiate the TAVVE pivotal trial, representing the first FDA-approved U.S. pivotal study evaluating a minimally invasive replacement venous valve for patients suffering from severe deep venous reflux.
The Company is developing the investigational enVVe® System, the first minimally invasive transcatheter replacement venous valve designed to restore one-way blood flow in the deep veins and directly address the underlying cause of chronic deep venous insufficiency. Building on the clinical foundation established by the Company's pioneering first-generation VenoValve technology, the enVVe® System is designed to advance the field through a minimally invasive transcatheter approach with the potential to expand physician adoption and improve patient access.
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease.
Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
INVESTOR CONTACT:
JTC Team, LLC
Jenene Thomas
NVNO@jtcir.com
(908) 824-0775
SOURCE: enVVeno Medical Corporation
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.